Eli Lilly and Company Sees Unusually Large Options Volume (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) was the target of unusually large options trading on Wednesday. Stock investors purchased 50,761 call options on the company. This is an increase of 30% compared to the typical volume of 39,145 call options.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on LLY shares. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research report on Thursday, February 19th. Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Scotiabank reissued an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, Bank of America reduced their price target on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,221.26.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Old North State Trust LLC lifted its position in shares of Eli Lilly and Company by 0.4% during the fourth quarter. Old North State Trust LLC now owns 7,414 shares of the company’s stock worth $7,968,000 after purchasing an additional 27 shares in the last quarter. J. Derek Lewis & Associates Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $1,196,000. Purpose Unlimited Inc. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $193,000. Stance Capital LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $1,480,000. Finally, Cornerstone Planning LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $4,226,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 4.0%

LLY stock traded up $37.17 during mid-day trading on Wednesday, hitting $956.94. 4,027,705 shares of the company were exchanged, compared to its average volume of 3,184,934. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a market capitalization of $904.13 billion, a P/E ratio of 41.75, a PEG ratio of 1.03 and a beta of 0.40. The business has a fifty day simple moving average of $1,001.75 and a 200-day simple moving average of $966.95. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the previous year, the firm earned $5.32 EPS. The business’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP?1 weight?loss pill Foundayo (orforglipron), broadening Lilly’s obesity portfolio with a convenient, scalable product and immediate commercial rollout via LillyDirect. Lilly’s weight-loss pill wins US approval — Reuters
• Positive Sentiment: Lilly agreed to acquire Centessa Pharmaceuticals (deal up to ~$7.8B), adding orexin?2 (OX2R) sleep?wake candidates and diversifying beyond GLP?1 into neuroscience — a strategic revenue?diversification move. Eli Lilly to buy Centessa Pharma in $6.3 billion deal — Reuters
• Positive Sentiment: Lilly expanded its AI drug?discovery push (multi?billion dollar program) to accelerate pipeline creation — supports long?term R&D productivity and the company’s premium valuation narrative. Eli Lilly bets on AI drugs in $2.75B deal — Yahoo Finance
• Positive Sentiment: Analyst commentary highlights Lilly’s strong earnings?surprise history and a setup that could support another beat in coming quarters, reinforcing investor confidence in cash?flow durability. Will Lilly beat estimates again? — Zacks
• Neutral Sentiment: Market commentators and TV personalities (e.g., Jim Cramer) are featuring Lilly in daily shows, increasing retail attention but with mixed short?term impact. Cramer’s Mad Dash: Eli Lilly — YouTube
• Negative Sentiment: Lilly’s CEO publicly opposes a White House push to codify “Most Favored Nations” drug?pricing deals into law — signals added regulatory/policy risk that could pressure margins or pricing dynamics. Eli Lilly opposes push to pass Trump’s MFN drug pricing deals into law — CNBC
• Negative Sentiment: Rival Novo Nordisk rolled out subscription pricing for Wegovy (and its pill), undercutting cash?pay pricing and intensifying competition in the GLP?1 market — a margin and market?share headwind to monitor. Novo launches Wegovy subscription pricing — Blockonomi
• Negative Sentiment: Guggenheim has trimmed expectations for Lilly’s stock price, signaling some sell?side caution on valuation even as fundamentals remain strong. Guggenheim lowers expectations for LLY — American Banking News

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.